US Stock MarketDetailed Quotes
EDIT Editas Medicine
- 2.200
- -0.010-0.45%
Close Nov 27 16:00 ET
- 2.230
- +0.030+1.36%
Post 20:01 ET
181.61MMarket Cap-866P/E (TTM)
2.280High2.180Low1.64MVolume2.240Open2.210Pre Close3.65MTurnover2.12%Turnover RatioLossP/E (Static)82.55MShares11.69052wk High1.03P/B170.11MFloat Cap2.13552wk Low--Dividend TTM77.32MShs Float99.950Historical High--Div YieldTTM4.53%Amplitude2.135Historical Low2.221Avg Price1Lot Size
Editas Medicine Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -48.31%-52.59M | -47.41%-57.06M | -39.43%-49.87M | 25.47%-132.18M | 47.39%-22.24M | 26.13%-35.46M | -2.29%-38.71M | 27.34%-35.77M | -8.27%-177.35M | -22.24%-42.27M |
| Net income from continuing operations | -38.03%-62.14M | -67.80%-67.61M | -26.34%-61.95M | 30.49%-153.22M | 68.93%-18.87M | 19.21%-45.02M | 24.63%-40.29M | 2.93%-49.04M | -14.51%-220.43M | -46.58%-60.74M |
| Operating gains losses | ---- | ---- | ---- | ---- | ---- | --0 | --0 | --1.58M | ---- | ---- |
| Depreciation and amortization | 5.61%1.6M | -7.79%1.42M | -8.74%1.41M | -4.31%6.06M | -7.04%1.47M | -5.61%1.51M | -3.63%1.54M | -0.90%1.54M | 25.41%6.34M | 4.37%1.58M |
| Other non cash items | --0 | ---- | ---- | --1.6M | ---- | ---- | ---- | ---- | ---- | ---- |
| Change In working capital | -4.89%4.34M | 245.81%6.41M | -24.13%4.8M | -119.50%-1.59M | -167.27%-8.09M | 777.31%4.56M | -158.08%-4.4M | 153.01%6.33M | 138.19%8.18M | 555.55%12.02M |
| -Change in receivables | 186.76%118K | 100.05%1K | 102.77%9.94M | -3.36%-5.04M | -54.53%-7.77M | -122.93%-136K | -410.17%-2.04M | 543.71%4.9M | -184.38%-4.88M | -31,306.25%-5.03M |
| -Change in prepaid assets | 570.00%1.07M | 326.19%2.14M | -203.15%-1.61M | -43.80%-197K | -118.02%-968K | -86.83%160K | -17.06%-947K | 1,673.74%1.56M | -103.67%-137K | -119.16%-444K |
| -Change in payables and accrued expense | -105.04%-239K | 179.78%3.58M | -577.01%-4.15M | -82.37%2.62M | -89.05%1.5M | 1,119.35%4.74M | -176.49%-4.49M | 120.66%870K | 380.36%14.87M | 92.41%13.68M |
| -Change in other current assets | 72.19%4.09M | -237.36%-4.17M | -76.95%1.34M | 141.67%6.63M | 75.70%-4.58M | 227.17%2.37M | 17.69%3.03M | 162.51%5.8M | -309.90%-15.92M | -830.19%-18.84M |
| -Change in other current liabilities | 72.89%-698K | 10,012.50%4.85M | 89.38%-723K | -131.93%-5.61M | -83.55%3.73M | -346.88%-2.58M | 101.65%48K | -111.76%-6.81M | 267.41%17.57M | 786.66%22.65M |
| -Change in other working capital | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 85.32%-3.33M | --0 |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -48.31%-52.59M | -47.41%-57.06M | -39.43%-49.87M | 25.47%-132.18M | 47.39%-22.24M | 26.13%-35.46M | -2.29%-38.71M | 27.34%-35.77M | -8.27%-177.35M | -22.24%-42.27M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 181.68%83.98M | 300.20%51.95M | -120.39%-4.75M | -103.27%-3.73M | 328.28%62.84M | -215.23%-102.82M | 424.39%12.98M | -58.73%23.27M | 309.43%114.07M | -20.53%-27.53M |
| Net PPE purchase and sale | -1,122.18%-2.92M | -162.12%-3.49M | -1.68%-1.87M | -15.10%-4.72M | -109.46%-1.31M | 61.07%-239K | -117.10%-1.33M | 18.15%-1.84M | 48.60%-4.1M | 78.07%-624K |
| Net investment purchase and sale | 184.71%86.9M | 287.34%55.45M | -111.45%-2.87M | -99.16%988K | 338.43%64.15M | -214.18%-102.58M | 522.52%14.32M | -57.17%25.11M | 354.18%118.17M | -34.55%-26.9M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 181.68%83.98M | 300.20%51.95M | -120.39%-4.75M | -103.27%-3.73M | 328.28%62.84M | -215.23%-102.82M | 424.39%12.98M | -58.73%23.27M | 309.43%114.07M | -20.53%-27.53M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 0 | -99.73%322K | 192K | 9,093.07%118.04M | -16.96%514K | 0 | 31,923.16%117.53M | 0 | -99.54%1.28M | -41.44%619K |
| Net common stock issuance | --0 | ---- | ---- | --117.08M | --0 | --0 | ---- | ---- | --0 | --0 |
| Proceeds from stock option exercised by employees | --0 | -27.80%322K | --192K | -25.23%960K | -16.96%514K | --0 | 21.53%446K | --0 | -96.07%1.28M | -41.38%619K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | --0 | -99.73%322K | --192K | 9,093.07%118.04M | -16.96%514K | --0 | 31,923.16%117.53M | --0 | -99.54%1.28M | -41.44%619K |
| Net cash flow | ||||||||||
| Beginning cash position | -69.60%68.32M | -44.99%73.1M | -12.29%127.53M | -29.89%145.4M | -59.73%86.42M | 29.67%224.69M | -38.12%132.9M | -29.89%145.4M | 44.47%207.4M | -18.65%214.58M |
| Current changes in cash | 122.70%31.39M | -105.21%-4.79M | -335.37%-54.43M | 71.18%-17.87M | 159.43%41.11M | -434.79%-138.28M | 321.30%91.8M | -269.80%-12.5M | -197.12%-62M | -22.74%-69.18M |
| End cash Position | 15.38%99.71M | -69.60%68.32M | -44.99%73.1M | -12.29%127.53M | -12.29%127.53M | -59.73%86.42M | 29.67%224.69M | -38.12%132.9M | -29.89%145.4M | -29.89%145.4M |
| Free cash flow | -55.50%-55.51M | -51.22%-60.56M | -37.59%-51.74M | 24.56%-136.9M | 45.11%-23.55M | 26.57%-35.7M | -4.07%-40.04M | 26.94%-37.61M | -5.64%-181.47M | -14.62%-42.9M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
